Increased farnesyltransferase activity in human colorectal cancer: Relationship with clinicopathological features and K-ras mutation

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 1, 2003, Pages 80-85

  Caruso, M G ^a   Notarnicola, M ^a   Bifulco, M ^a   Laezza, C ^a   Guerra, V ^a   Altomare, D F ^a   Memeo, V ^a   Lorusso, D ^a   Demma, I ^a   Di Leo, Alfredo ^a  

^a National Institute for Digestive Diseases   (Italy)

Author keywords

Colorectal cancer; Farnesyltransferase activity; K ras mutation

Indexed keywords

MESSENGER RNA; PROTEIN FARNESYLTRANSFERASE;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBUNIT; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADENOCARCINOMA; AGED; ALKYL AND ARYL TRANSFERASES; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FARNESYLTRANSTRANSFERASE; FEMALE; GENES, RAS; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 0037255268     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000483     Document Type: Article

References (37)

1. Clarke S. Protein isoprenylation and methylation at carboxylterminal cysteine residues. Annu Rev Biochem 1992;61:355-86.
2. Farnsworth CC, Wolda SL, Gelb MH, Glomset JA. Human lamin B contains a farnesylated cysteine residue. J Biol Chem 1989;264:20422-9.
3. Sinensky M, Famtle K, Triyillo M, McLain T, Kupfer A, Dalton M. The processing pathway of prelamin A. J Cell Sci 1994;107:61-7.
4. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, et al. FTIs block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-7.
5. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, Pallen CJ. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane and the early endosome. J Biol Chem 2000;275:21444-52.
6. Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, Brown MS. Non-identical subunits of p21 Ras-farnesyltransferase: peptide binding and farnesylpirophosphate carrier functions. J Biol Chem 1991;266:10672-7.
7. ras farnesyl protein transferase by cys-AAX tetrapeptides. Cell 1990;62:81-8.
8. Manne V, Roberts D, Tobin A, O'Rourke E, De Virgilio M, Meyers C. et al. Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 1990;87:7541-5.
9. Agarwal R, Khan SG, Athar M, Zaidi SY, Bichers DR, Mukhtar H. Ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. Mol Carcinog 1993;8:290-8.
10. Downward J. Ras signaling and apoptosis. Curr Opin Genet Dev 1998;8:49-54.
11. Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
12. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to ras proteins is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 1992;89:6403-7.
13. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 1999;17:3631-52.
14. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational mechanism-based treatment for hematologic malignancies? Blood 2000;96:1655-69.
15. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA. Farnesyltransferase inhibitors is mediated by gain of geranylgeranylated Rho B. J Biol Chem 1997;272:15591-4.
16. Du W, Lebowitz PF, Prendergast GC. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated Rho B. Mol cell Biol 1999;9:1831-40.
17. Jiang K, Coppola D, Crespo NC, Nicosia SV, Hamilton AD, Sebti SM, et al. The phosphoinositide3-OH Kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol Cell Biol 2000;20:139-48.
18. Chen Z, Sun J, Pradines A, Favre G, Adnane J, Sebti SM. Both farnesylated and geranylgeranylated Rho B inhibit malignant transformation and suppress human tumor growth in nude mice. J Biol Chem 2000;275:17974-8.
19. Laezza C, Di Marzo V, Bifulco M. v-K-ras leads to preferential farnesylation of p21(ras) in FRTL-5 cells: multiple interference with the isoprenoid pathway. Proc Natl Acad Sci USA 1998;95:13646-51.
20. Khan SG, Dummer R, Siddiqui J, Bickers DR, Agarwal R, Mukhtar H. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. Biochem Biophys Res Comm 1996;220:795-801.
21. Tanimoto H, Mehta KD, Parmley TH, Shigemasa K, Parham GP, Clarke J, et al. Expression of the farnesyltransferase β-subunit gene in human ovarian carcinoma: correlation to K-ras mutation. Gynecol Oncol 1997;66:308-12.
22. Nagase T, Kawata S, Nakajima H, Tamura S, Yamasaki E, Fukni K, et al. Effect of farnesyltransferase overexpression on cell growth and transformation. Int J Cancer 1999;80:126-33.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193:265-67.
24. Wright J, Blatner GL, Cheson BD. Clinical trials referral resource. Clinical trials with the farnesyltransferase inhibitor R 115777. Oncology 1999;13:1527-33.
25. Adjei AA, Erlichman C, Davis JN, Cutler D, Sloan JA, Marks RS, et al. A Phase I trial of the farnesyltransferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res 2000;60:1871-7.
26. Eskens F, Awada A, Verweig J, Cutler DL, Hanauske A, Piccart M. Phase I and pharmacocinetic study of the oral Ftase inhibitor SCH66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 2001;19:1167-75.
27. Zujewski BJ, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2000;18:927-41.
28. Gokmen-Polar Y, Murray NR, Velasco MA, Gatalica Z, Fields AP. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res 2001;61:1375-81.
29. Bos J, Fearon ER, Hamilton SR, Verlaaan-de Vries M, van Boon JH, van der Eb AJ, et al. Prevalence of ras gene mutation in human colorectal cancers. Nature 1987;327:293-7.
30. Cooper GM, Lane MA. Cellular transforming genes and oncogenesis. Biochem Biophys Acta 1984;738:9-20.
31. Sepp-Lorenzino L, Rao S, Coleman PS. Cell-cycle-dependent differential prenylation of proteins. Eur J Biochem 1991;200:579-90.
32. Schulz S, Klam RC, Schonfeld S, Nyce JW. Mechanisms of cell growth inhibition and cell cycle arrest in human colonic adenocarcinoma cells by dehydroepiandrosterone: role of isoprenoid biosynthesis. Cancer Res 1992;52:1372-6.
33. Caruso MG, Osella AR, Notarnicola M, Berloco P, Leo S, Bonfiglio C, et al. Prognostic value of LDL-receptor expression in colorectal carcinoma. Oncol Rept 1998;5:927-30.
34. Caruso MG, Notarnicola M, Santillo M, Cavallini A, Di Leo A. Enhanced 3-HMG-CoA reductase activity in human colorectal cancer not expressing low density lipoprotein receptor. Anti-cancer Res 1999;19:451-4.
35. 2-Isopentenyl tRNA from mevalonate in cultured human fibroblasts. J Biol Chem 1980;255:6546-8.
36. Pocard M, Salmon RJ, Muleris M, Remvikos Y, Bora J, Dutillaux B, et al. Deux colons-deux cancers? Adenocarcinomas coliques proximal ou distal: arguments en faveur d'une cancerogenese distincte. Bull Cancer 1995;82:10-21.
37. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779-88.